MGTA-117 Antibody

Cat. No.: HY-P991294: Data Sheet
FAQs
Technical Support

MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy.

For research use only. We do not sell to patients.

MGTA-117 Antibody Chemical Structure

Size		Stock
MOQ		Minimum order quantity
1 mg		Get quote
5 mg		Get quote
10 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description	MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy^[1]^[2]^[3].
In Vitro	MGTA-117 (0.1-1.0 mg/kg) rapidly and selectively binds and depletes CD117+ cells (human hematopoietic stem cells and AML tumor cells) with IC₅₀ s of <10 pM^[1]. MGTA-117 effectively depletes more than 95% of human hematopoietic stem and progenitor cells (HSPCs) in AML murine models^[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. MGTA-117 Antibody Related Antibodies
In Vivo	MGTA-117 (0.1 mg/kg, i.v., once for 21 days) has a short half-life with a t_1/2 of 91 h and selectively depletes ≥95% HSPCs in humanized NSG (hNSG) mice^[1,2]. MGTA-117(3 & 10 mg/kg, once or 3 mg/kg, QODx2) significantly increases survival of a 2.4-2.7-fold in Kasumi-1 xenograft hNSG mice model^[2]. MGTA-117 (3 & 10 mg/kg, once) significantly decreases peripheral tumor burden, delays tumor growth, and increases survival in AML PDX 1 (2-3.3 fold) and AML PDX 2 (1.3-1.8 fold) xenograft hNSG mice models^[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
SMILES	[MGTA-117 Antibody]
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (260 KB) Inhibitory Antibodies User Guide (602 KB)
References	[1]. Artz A S, et al. TIP: A phase I/II study of MGTA-117, an anti-CD117 antibody-drug conjugate, in patients with adult acute myeloid leukemia (AML) and myelodysplasia with excess blasts (MDS-EB) [J]. 2022. [2]. Lanieri L, et al. A single dose of a novel anti-human CD117-amanitin antibody drug conjugate (ADC) engineered for a short half-life provides dual conditioning and anti-leukemic activity and extends survival compared to standard of care in multiple preclinical models of acute myeloid leukemia (AML)[J]. Blood, 2020, 136: 47-48. [3]. Kitawi R, et al. Advances in HIV Gene Therapy. Int J Mol Sci. 2024 Feb 28; 25(5):2771. [Content Brief]